In Collaboration With:
Covid-19 has impacted activities globally across society including pharmacovigilance without any end date to this pandemic.
Regulators have provided expectations during this crisis but what are the practical implications?
This webinar will reflect on range of questions that arise including:
- How should we adjust our priorities and where should we be extra vigilant?
- How long do business continuity plans last before quality systems must be changed?
- Are there opportunities for more efficient practice leading to more efficient pharmacovigilance
